246 related articles for article (PubMed ID: 32537950)
1. Intravenous Glucocorticoid Treatment for Korean Graves' Ophthalmopathy Patients.
Ahn HY; Lee JK
J Korean Med Sci; 2020 Jun; 35(23):e177. PubMed ID: 32537950
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tripterygium glycosides for active moderate to severe Graves' ophthalmopathy: a randomised, observer-masked, single-centre trial.
Ye X; Zhao H; Liu J; Lu B; Shao J; Wang J
Eur J Endocrinol; 2021 Feb; 184(2):277-287. PubMed ID: 33539318
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
6. Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves' ophthalmopathy.
Ueda-Sakane Y; Kanamoto N; Fushimi Y; Tanaka-Mizuno S; Yasuno S; Miura M; Sone M; Yasoda A; Okada T; Togashi K; Nakao K; Inagaki N
Endocr J; 2016 Aug; 63(8):703-14. PubMed ID: 27263854
[TBL] [Abstract][Full Text] [Related]
7. Three dimensional orbital magnetic resonance T2-mapping in the evaluation of patients with Graves' ophthalmopathy.
Hou K; Ai T; Hu WK; Luo B; Wu YP; Liu R
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):938-942. PubMed ID: 29270757
[TBL] [Abstract][Full Text] [Related]
8. VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY.
Leo M; Mautone T; Ionni I; Profilo MA; Sabini E; Menconi F; Mazzi B; Rocchi R; Latrofa F; Nardi M; Vitti P; Marcocci C; Marinò M
Endocr Pract; 2016 Oct; 22(10):1177-1186. PubMed ID: 27732097
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.
Currò N; Covelli D; Vannucchi G; Campi I; Pirola G; Simonetta S; Dazzi D; Guastella C; Pignataro L; Beck-Peccoz P; Ratiglia R; Salvi M
Thyroid; 2014 May; 24(5):897-905. PubMed ID: 24417307
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
11. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.
Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G
J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of serum immunoglobulin G4 in glucocorticoid therapy of Graves' ophthalmopathy.
Li Y; Luo B; Zhang J; Zhou X; Shao S; Xu W; Yang Y; Yuan G
Clin Endocrinol (Oxf); 2021 Oct; 95(4):657-667. PubMed ID: 33938028
[TBL] [Abstract][Full Text] [Related]
13. [Short-term efficacies of intravenous glucocorticoid therapy for moderate-to-severe Graves' ophthalmopathy].
Guo L; Yang G; Gu W; Jin N; Chen K; Du J; Wang X; Ouyang J; Dou J; Ba J; Lü Z; Mu Y
Zhonghua Yi Xue Za Zhi; 2015 May; 95(20):1572-5. PubMed ID: 26463604
[TBL] [Abstract][Full Text] [Related]
14. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combined parenteral and oral steroid therapy in Graves' orbitopathy.
Nedeljkovic Beleslin B; Ciric J; Zarkovic M; Stojkovic M; Savic S; Knezevic M; Stankovic B; Trbojevic B
Hormones (Athens); 2014; 13(2):222-8. PubMed ID: 24776622
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two different regimens of intravenous methylprednisolone for patients with moderate to severe and active Graves' ophthalmopathy: a prospective, randomized controlled trial.
He Y; Mu K; Liu R; Zhang J; Xiang N
Endocr J; 2017 Feb; 64(2):141-149. PubMed ID: 27853049
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy.
Ponto KA; Kanitz M; Olivo PD; Pitz S; Pfeiffer N; Kahaly GJ
Ophthalmology; 2011 Nov; 118(11):2279-85. PubMed ID: 21684605
[TBL] [Abstract][Full Text] [Related]
19. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
20. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study.
Ng CM; Yuen HK; Choi KL; Chan MK; Yuen KT; Ng YW; Tiu SC
Hong Kong Med J; 2005 Oct; 11(5):322-30. PubMed ID: 16219950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
